# Effect of RANKL Inhibition on UV-induced Immunosuppression

> **NCT01978483** · PHASE1 · COMPLETED · sponsor: **Innovaderm Research Inc.** · enrollment: 31 (actual)

## Conditions studied

- Ultraviolet Rays
- Immunosuppression
- Hypersensitivity, Delayed
- Immune Tolerance/Drug Effects

## Interventions

- **DRUG:** Denosumab
- **RADIATION:** UVB exposure
- **DRUG:** Diphenylcyclopropenone
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT01978483
- **Lead sponsor:** Innovaderm Research Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2014-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01978483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01978483, "Effect of RANKL Inhibition on UV-induced Immunosuppression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01978483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*